His main research concerns Internal medicine, Pancreatic cancer, Oncology, Cancer and Prospective cohort study. His research is interdisciplinary, bridging the disciplines of Endocrinology and Internal medicine. His Pancreatic cancer research incorporates themes from Odds ratio, Precision medicine, Cancer research, Case-control study and Pancreas.
His Odds ratio study combines topics from a wide range of disciplines, such as Gastroenterology, Genetics and Genome-wide association study. His biological study spans a wide range of topics, including Malignancy, Irinotecan, Oxaliplatin, Colorectal cancer and Radiation therapy. The various areas that Brian M. Wolpin examines in his Prospective cohort study study include Spearman's rank correlation coefficient, Chromatography, Metabolomics and Metabolite.
The scientist’s investigation covers issues in Internal medicine, Pancreatic cancer, Oncology, Cancer and Cancer research. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Endocrinology. The study incorporates disciplines such as Odds ratio, Genome-wide association study, Single-nucleotide polymorphism, Case-control study and Adenocarcinoma in addition to Pancreatic cancer.
As part of the same scientific family, Brian M. Wolpin usually focuses on Oncology, concentrating on Irinotecan and intersecting with Oxaliplatin. His Cancer study which covers Risk factor that intersects with Relative risk and Pancreatic disease. His work investigates the relationship between Cancer research and topics such as Phenotype that intersect with problems in Cell.
His scientific interests lie mostly in Pancreatic cancer, Internal medicine, Cancer research, Oncology and Cancer. Pancreatic cancer is a subfield of Genetics that he tackles. His Gastroenterology research extends to Internal medicine, which is thematically connected.
Brian M. Wolpin has researched Cancer research in several fields, including Phenotype, Carcinogenesis, Tumor microenvironment, Immune system and Organoid. His Oncology research includes themes of Genetic counseling, Prospective cohort study, Borderline resectable and Germline. Brian M. Wolpin interconnects Immunofluorescence and Biomarker in the investigation of issues within Cancer.
Brian M. Wolpin mainly focuses on Pancreatic cancer, Internal medicine, Oncology, Disease and Cancer. Brian M. Wolpin has included themes like Tumor microenvironment, Cancer research, Flow cytometry and Circulating biomarkers in his Pancreatic cancer study. His Internal medicine research is multidisciplinary, incorporating elements of Diabetes mellitus and Gastroenterology.
His work carried out in the field of Oncology brings together such families of science as Neoadjuvant therapy, Borderline resectable, Chemotherapy and Adenocarcinoma. The various areas that Brian M. Wolpin examines in his Disease study include Incidence and MEDLINE. His study in Cancer is interdisciplinary in nature, drawing from both Heritability, Relative risk, Genetic predisposition and Medical genetics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
Laufey Amundadottir;Peter Kraft;Rachael Z. Stolzenberg-Solomon;Charles S. Fuchs.
Nature Genetics (2009)
Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology
Margaret A. Tempero;Mokenge P. Malafa;Mahmoud Al-Hawary;Horacio Asbun.
Journal of The National Comprehensive Cancer Network (2017)
Systemic Treatment of Colorectal Cancer
Brian M. Wolpin;Robert J. Mayer.
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33
Gloria M. Petersen;Laufey Amundadottir;Charles S. Fuchs;Peter Kraft.
Nature Genetics (2010)
Detectable clonal mosaicism and its relationship to aging and cancer
Kevin B. Jacobs;Kevin B. Jacobs;Meredith Yeager;Meredith Yeager;Weiyin Zhou;Weiyin Zhou;Sholom Wacholder.
Nature Genetics (2012)
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Vasanthi S. Viswanathan;Matthew J. Ryan;Harshil D. Dhruv;Shubhroz Gill.
ABO Blood Group and the Risk of Pancreatic Cancer
Brian M. Wolpin;Andrew T. Chan;Patricia Hartge;Stephen J. Chanock.
Journal of the National Cancer Institute (2009)
Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development
Jared R Mayers;Chen Wu;Chen Wu;Clary B Clish;Peter Kraft.
Nature Medicine (2014)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin;Aram F. Hezel;Thomas Abrams;Lawrence S. Blaszkowsky.
Journal of Clinical Oncology (2009)
Adjuvant treatment of colorectal cancer.
Brian M. Wolpin;Jeffrey A. Meyerhardt;Harvey J. Mamon;Robert J. Mayer.
CA: A Cancer Journal for Clinicians (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: